Northern Trust’s Ascendis Pharma A/S ASND Stock Holding History

Northern Trust’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.3M	Buy	44,971 +12,117	+37%	+$2.72M	﹤0.01%	2060
2025 Q4	$7.01M	Buy	32,854 +17,297	+111%	+$3.57M	﹤0.01%	2276
2025 Q3	$3.09M	Buy	+15,557	New	+$2.9M	﹤0.01%	2785
2025 Q2	–	Sell	-1,592	Closed	-$248K	–	4408
2025 Q1	$248K	Buy	+1,592	New	+$227K	﹤0.01%	3865
2018 Q1	–	Sell	-12,857	Closed	-$515K	–	4249
2017 Q4	$515K	Buy	+12,857	New	+$467K	﹤0.01%	3554

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Trust's ASND Position: Q1 2026 in Review

Northern Trust increased its Ascendis Pharma A/S (ASND) stake by 37% in Q1 2026, buying an estimated $2.72M and bringing the position to 44,971 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2060.

Northern Trust first reported a position in ASND in Q4 2017 and has held it in 5 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Northern Trust held 44,971 shares of Ascendis Pharma A/S worth $10.3M as of Q1 2026.
Northern Trust bought 12,117 Ascendis Pharma A/S shares in Q1 2026, an estimated $2.72M.
Ascendis Pharma A/S made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2060 holding.
Northern Trust first reported a position in Ascendis Pharma A/S in Q4 2017 and has held it in 5 quarters since.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.